Literature DB >> 2933926

Nephrotoxicity of ionic and non-ionic contrast media in aorto-femoral angiography.

U Albrechtsson, B Hultberg, H Lárusdóttir, L Norgren.   

Abstract

Nineteen patients examined with aorto-femoral angiography were randomized into two contrast medium groups (meglumine metrizoate and iohexol). Urine activity of beta-hexosaminidase, a specific renal enzyme, was determined before and on three occasions after angiography. No change of beta-hexosaminidase activity was found after angiography with iohexol, while there was a significant increase after examination with meglumine metrizoate. This indicates that meglumine metrizoate even following injection into the abdominal aorta damages renal cells which could not be shown with iohexol as contrast medium. We therefore recommend that at least patients with impaired renal function should be examined with the non-ionic contrast medium iohexol to minimize the danger of further damage to the kidneys and a possible renal failure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933926     DOI: 10.1177/028418518502600519

Source DB:  PubMed          Journal:  Acta Radiol Diagn (Stockh)        ISSN: 0567-8056


  3 in total

1.  Iohexol contrast medium induces QT prolongation in amiodarone patients.

Authors:  Matthias Goernig; Thomas Kirmeier; Andreas Krack; Christiane S Hartog; Hans R Figulla; Uwe Leder
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

2.  Iohexol Clearance for the Determination of Glomerular Filtration Rate: 15 Years' Experience in Clinical Practice.

Authors:  Peter Nilsson-Ehle
Journal:  EJIFCC       Date:  2001-07-22

Review 3.  Is contrast medium osmolality a causal factor for contrast-induced nephropathy?

Authors:  Andreas M Bucher; Carlo N De Cecco; U Joseph Schoepf; Felix G Meinel; Aleksander W Krazinski; James V Spearman; Andrew D McQuiston; Rui Wang; Judith Bucher; Thomas J Vogl; Richard W Katzberg
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.